Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.94 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market cap of $51.39 million, a PE ratio of -2.61 and a beta of 0.57. The firm has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $1.01. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the third quarter valued at approximately $51,000. CM Management LLC boosted its holdings in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Finally, Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.